View Older Stories View More Recent Stories

Jan 13, 2025 07:04AM Moderna (MRNA) updates 2025 expected revenue range to $1.5 to 2.5 billion
Jan 13, 2025 07:00AM Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Nov 25, 2024 07:00AM Moderna to Present at Upcoming Conferences in December 2024
Nov 20, 2024 08:00AM Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies
Nov 13, 2024 08:00AM Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio
Nov 12, 2024 08:15AM Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
Nov 8, 2024 07:34AM Moderna (MRNA) Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
Nov 8, 2024 07:30AM Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
Nov 7, 2024 06:30AM Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Oct 31, 2024 07:00AM Moderna to Present at Upcoming Conferences in November 2024
Oct 28, 2024 06:46AM Merck (MRK) and Moderna (MRNA) Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA
Oct 28, 2024 06:45AM Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types
Oct 24, 2024 02:25PM Moderna Named a Top Employer by Science for Tenth Consecutive Year
Oct 17, 2024 07:05AM Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
Oct 3, 2024 08:00AM Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
Oct 2, 2024 07:03AM Moderna (MRNA) Appoints Abbas Hussain to its Board
Oct 2, 2024 07:00AM Abbas Hussain Joins Moderna's Board of Directors
Oct 1, 2024 06:17AM Moderna (MRNA) and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan
Sep 30, 2024 08:00PM Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
Sep 30, 2024 07:24AM Moderna (MRNA) Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
Sep 30, 2024 07:00AM Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
Sep 17, 2024 11:03AM Moderna (MRNA) Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant
Sep 17, 2024 11:00AM Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
Sep 12, 2024 06:03AM Moderna (MRNA) R&D Day Highlights Progress and Strategic Priorities
Sep 12, 2024 06:00AM Moderna R&D Day Highlights Progress and Strategic Priorities
Sep 9, 2024 07:32AM Moderna's (MRNA) Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
Sep 9, 2024 07:00AM Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
Sep 5, 2024 08:04AM Moderna (MRNA) Reports EMA CHMP's Positive Opinion of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Sep 5, 2024 08:00AM EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Sep 4, 2024 08:30AM Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
Sep 3, 2024 08:34AM Moderna (MRNA) Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
Sep 3, 2024 08:30AM Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
Sep 2, 2024 07:00AM Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Aug 23, 2024 07:03AM Moderna (MRNA) Receives European Commission Approval for RSV Vaccine mRESVIA(R)
Aug 23, 2024 07:00AM Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
Aug 23, 2024 01:25AM Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1
Aug 22, 2024 01:59PM Moderna (MRNA) Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
Aug 22, 2024 07:00AM Moderna to Host Investor Event - R&D Day and Business Updates
Aug 22, 2024 12:00AM Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
Aug 14, 2024 07:00AM Moderna and Coursera Launch Free Course on mRNA Technology
Aug 1, 2024 06:30AM Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
Jul 25, 2024 08:00AM Analog Devices and Flagship Pioneering Announce Strategic Partnership to Accelerate the Development of a Fully Digitized Biological World
Jul 23, 2024 10:35AM Moderna (MRNA) Appoints David Rubenstein to its Board
Jul 23, 2024 07:00AM David Rubenstein Joins Moderna's Board of Directors
Jul 23, 2024 06:00AM Flagship Pioneering Unveils Abiologics to Pioneer Supranatural Biologics, A New Biotherapeutic Class
Jul 10, 2024 07:00AM Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
Jul 9, 2024 05:41AM Moderna (MRNA) Partners with Mitsubishi Tanabe Pharma to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines
Jul 8, 2024 07:00PM Moderna And Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines
Jul 2, 2024 07:31AM Moderna (MRNA) Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
Jul 2, 2024 07:30AM Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
View More Recent Stories View Older Stories